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Abstract
In Italy the prevalence of recent HIV infection (RHI) isn’t currently monitored. Early diagnosis
is crucial to allow introduction of antiretroviral therapy (cART) in the recent phase of infec-
tion. We aimed to estimate the proportion and the determinants of RHI among patients
enrolled in the ICONA cohort; we explored differences in the median time from HIV diagno-
sis to cART initiation and in the viro-immunological response between RHI and Less Recent
HIV infections (NRHI). We included antiretroviral-naïve HIV-positive patients enrolled in the
cohort with documented dates of HIV-negative and positive antibodies tests, grouped in RHI
(estimated date of seroconversion within 12 months of enrolment) and NRHI. Proportion of
RHI and the trend of this proportion by calendar period (1996–2014) were investigated (Chi-
square test). Logistic regression analysis was employed to identify factors associated with
RHI. The time from seroconversion to cART initiation was compared in RHI and NRHI over-
all and after stratification by calendar period (survival analysis). We finally explored the time
from starting cART to HIV-RNA <50 copies/mL and to CD4+ gain200 cells/mmc by Cox
regression. HIV seroconversion could be estimated for 2608/12,616 patients: 981/2608
(37.6%) were RHI. Proportion of RHI increased in recent calendar periods and was associ-
ated with younger age, baseline higher HIV-RNA and CD4+ count. There wasn’t difference
in the 2-year estimates of cART start between RHI and NRHI, regardless of calendar period.
Rates and hazards of virological response were similar in RHI versus NRHI. RHI showed a
1.5-fold higher probability of CD4+ gain, also following adjustment for calendar period and
cART regimen, and for age, HCV and smoking; the difference in probability was however
attenuated after further controlling for baseline HIV-RNA and CD4+ T-cells. The increased
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proportion of RHI over time suggests that in recent years in Italy HIV infections are more
likely to be detected earlier than before. The similar rates of cART introduction and viro-
immunological response in RHI and NRHI probably reflect the efficacy of the modern cART
regimens. An improvement of the prevention services is warranted to allow an early cART
access, also in the perspective of therapy as prevention.
Introduction
Recent HIV Infection (RHI) is defined by a negative HIV antibody test within 6/12 months of
diagnosis [1–3]. Recently the CASCADE collaboration published the largest study of serocon-
verters cohorts from 25 countries to estimate the rates of immunological decline and survival
in HIV-positive patients; they found that mean age at seroconversion was 31.1 years for 16373
patients and 6947 started cART. Lower CD4+ counts at seroconversion and higher mortality
rates were reported in HIV-positive patients infected at an older age [4]. Early diagnosis is cru-
cial to insure benefit for the individual due to early access to care and cART, especially now
that immediate treatment is recommended for all patients, and to reduce HIV transmission at
population level [5–7]. Two recent studies have demonstrated the health benefits of an early
initiation of cART for asymptomatic HIV-infected patients with high CD4+ counts: when
cART was immediately started instead of waiting until CD4+ count was <350 cells/mmc,
there was a reduction of over 40% in the risk of death or AIDS defining disease [6, 8]. In partic-
ular, early treatment leads to better immune recovery [9, 10], HIV reservoir decline [11, 12]
and reduction of new infections, considering the high rate of transmissions during RHI [2, 3,
13]. In Italy new HIV diagnoses are reported to the Healthcare System; public health surveil-
lance captures new diagnoses irrespective of time of HIV infection. Given the lack of current
monitoring of RHI prevalence in Italy, we aimed to use the ICONA Foundation Study cohort
to estimate the proportion and determinants of HIV infections diagnosed during the recent
phase over the period 1996 to 2014; RHI was defined as having an estimated date of serocon-
version within 12 months from the date of enrolment in the cohort. We also explored the dif-
ferences in the time from seroconversion to cART initiation and in viro-immunological
response under treatment between RHI and less recent infections (non RHI, NRHI).
Materials and methods
We conducted an observational retrospective longitudinal study over 1996–2014. We included
untreated HIV-positive patients with documented dates of HIV-negative and positive antibod-
ies tests enrolled in the ICONA Foundation Study cohort. The Icona Foundation Study cohort
is an observational multicentre cohort that enrolls HIV-infected individuals who are antiretro-
viral-naïve at the time of enrolment. A detailed description of the cohort is reported elsewhere
[14]. Patients are voluntary enrolled by physicians at the different centres in Italy participating
in ICONA Study after signing an informed consent. This cohort was set up in January 1997
and currently includes data on patients enrolled at 51 infectious disease units in Italy.
Participants’ date of HIV seroconversion was estimated as the midpoint between the last
available HIV-negative and the first available HIV-positive test. People with such a date
recorded within 1 year (since the last negative HIV serological test) were defined as RHI,
according to current definition [2]. The proportion of RHI was calculated for the following cal-
endar periods: 1996–2000, 2001–2006, 2007–2009, 2010–2014. Because the rate of enrolment
in the cohort has been varying over time, the group period classification was based on the
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quantile of the distribution of enrolments in the cohort in order to have similar denominators
in each calendar period.
AIDS defining conditions were diagnosed according to CDC revised classification system
in 1993 [15]. Patients with hepatitis co-infection were defined as HCV Ab or HBsAg positive
subjects. The proportion of RHI at entry in the cohort and the trend of this proportion by cal-
endar period of enrolment were investigated using a Chi-square test. Univariable and multi-
variable logistic regression analysis was employed to identify factors associated with RHI. All
the variables associated with the outcome with a p value <0.01 in the univariable analysis were
selected for inclusion in the multivariable model; we thus included the following factors in the
multivariable analysis: calendar period of seroconversion, gender, age, mode of HIV transmis-
sion, AIDS diagnosis, CD4+ T-cells and HIV-RNA (measured at enrolment), HCV co-infec-
tion, site geographical position, employment status, smoking and blood glucose. Survival
analysis techniques were used to compare the time from seroconversion to cART initiation in
RHI and NRHI, overall and after stratification by calendar period of enrolment (Kaplan-Meier
method with log-rank test). We investigated the proportion of patients achieving a HIV-RNA
500 copies/mL at 6 months (time window +3; +9 months) from the date of starting cART,
stratified by RHI status and calendar period (missing values of HIV-RNA were excluded from
the analysis). We have chosen the threshold of 500 copies/mL, instead of 50 copies/mL,
because this was the lower limit of detection of the assay used at the sites in the early calendar
periods. We finally explored the determinants of probability of virological success (time from
cART start to confirmed HIV-RNA <50 copies/mL) and of CD4+ count recovery (time from
cART start to CD4+ gain200 cells/mmc) by univariable and multivariable Cox regression
models. We also performed a sensitivity analysis to explore the probability of immunological
recovery according to another definition: CD4+ gain of 200 cells/mmc or reaching a single
CD4+ count>350 cells/mmc, which ever came first.
The study was approved by the Ethical Committee of all the Centers participating to the
ICONA Foundation Study (see acknowledgments and Ethics Statement for the full name of
the ethics committees that approved the study). All patients signed written informed consent.
Statistical analyses were performed using SAS software package (SAS Institute).
Results
Proportion of Recent HIV Infections in the ICONA Foundation Study
cohort
Between 1996 and 2014 the date of HIV seroconversion could be estimated for 2608/12616
patients. Overall, 981/2608 (37.6%) patients were defined as RHI, with a trend for an increased
proportion in latest years: from 213/578 (36.9%) in 1996–2000 up to 526/927 (56.7%) in more
recent years (2010–2014; p<0.001) (Fig 1).
Table 1 shows the characteristics of the study population stratified by RHI status. RHI
patients were younger than NRHI subjects (median age was 34, IQR 28–40 years in RHI and
36, IQR 31–42 in NRHI, p<0.001); proportion of females and risk factors for HIV transmis-
sion were similar between the two groups of patients. RHI patients also presented higher CD4
+ T cells count in comparison with NRHI (CD4+ counts, cells/mmc: 493, IQR 336–667 in RHI
and 452, IQR 289–632 in NRHI, p<0.001) (Table 1). Median time from the estimated date of
seroconversion to entry in the cohort was 6 (IQR 4–9) in RHI and 27 (IQR 18–45) in NRHI
(p<0.001).
As regards the characteristics of patients enrolled in the study stratified by calendar period,
in 2010–2014 patients with a known date of seroconversion presented a median age of 33
years (IQR: 27–40), median CD4+ count was 479 cells/mmc (IQR: 331–629) and HIV-RNA
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4.65 log10 copies/mL (IQR: 4.11–5.16). With more recent years, we observed a reduction of
females, AIDS presenters, hepatitis B and C co-infected patients and intravenous drug users
(IDUs), but a sharp increase in men who have sex with men (MSM) and in people from north-
ern Italy. Higher baseline HIV-RNA has also been reported in more recent calendar periods.
Conversely, no difference in age and CD4+ count at enrolment was displayed (Table 2).
Factors associated with Recent HIV Infections in Italy over 1996–2014
Factors associated with RHI by fitting a multivariable logistic regression analysis were younger
age at HIV diagnosis, higher baseline CD4+ T-cells and HIV-RNA. More recent calendar
period (2010–2014) was also associated with a 12-fold higher probability of RHI versus 1996–
2000 (Table 3).
Estimates of cART initiation and of viro-immunological success in
Recent and Less Recent HIV Infections
Among all patients included in the analysis, 49% of participants started cART by 3 months
from seroconversion with no differences over time: 47.1% in 1996–2000, 49.4% in 2010–2014
(Table 2). There was also no difference in the 2-year cumulative probability of cART initiation
between RHI and NRHI, regardless of calendar period (74.2% in RHI, 74.1% in NRHI,
p = 0.73). The reasons for non cART initiation in the study population were the following: an
HIV diagnosis within 6 months of enrolment (58%), no indication for cART (25% which is
likely to be CD4+ count and guidelines driven), first access to care (13%), patients’ choice
(2%), physician’s choice (2%) and other/unknown (1%).
Fig 1. Proportion of Recent HIV Infections by calendar period of enrolment. The graph illustrates the
proportion of Recent HIV Infections (RHI), defined as a positive HIV serological test within 12 months since
the last negative one, according to calendar period of seroconversion (1996–2000, 2001–2006, 2007–2009,
2010–2014). X-axis: calendar periods, Y-axis: proportion of RHI in percentages.
https://doi.org/10.1371/journal.pone.0189045.g001
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Table 1. Characteristics of the study population according to RHI status.
Recent seroconversion
Characteristics Yes (RHI) No (NRHI) p-value Total
N 981 N 1627 N 2608
Age, years, median (IQR) 34 (28, 40) 36 (31, 42) <0.001 35 (30, 42)
Females, n (%) 117 (11.9%) 273 (16.8%) 1.000 390 (15.0%)
Mode of HIV Transmission, n (%) 0.501
IDUs 79 (8.1%) 164 (10.1%) 243 (9.4%)
Homosexual contacts 587 (59.9%) 893 (55.3%) 1480 (57.0%)
Heterosexual contacts 256 (26.1%) 489 (30.1%) 745 (28.6%)
Other/Unknown 58 (5.9%) 70 (4.3%) 128 (4.9%)
Not Italian nationality, n (%) 123 (12.5%) 212 (13.0%) 0.050 335 (12.8%)
AIDS diagnosis, n (%) 26 (2.7%) 67 (4.1%) 0.478 93 (3.6%)
CVD diagnosis, n (%) 3 (0.3%) 8 (0.5%) 0.295 11 (0.4%)
HBsAg, n (%) 0.036
Negative 947 (96.5%) 1582 (97.2%) 2529 (97.0%)
Positive 34 (3.5%) 45 (2.8%) 79 (3.0%)
Not tested 309 (31.5%) 553 (34.0%) 862 (33.1%)
HCV Ab, n (%) 0.161
Negative 606 (61.8%) 932 (57.3%) 1538 (59.0%)
Positive 80 (8.2%) 172 (10.6%) 252 (9.7%)
Not tested 295 (30.1%) 523 (32.1%) 818 (31.4%)
CD4 count, cells/mmc,
median (IQR)
493 (336, 667) 452 (289, 632) <0.001 469 (307, 651)
CD4 count nadir, cells/mmc,
median (IQR)
495 (338, 669) 452 (293, 625) <0.001 470 (309, 641)
CD8 count, cells/mmc,
median (IQR)
904 (654, 1284) 931 (688, 1283) 0.383 923 (675, 1283)
Viral load, log10 copies/mL,
median (IQR)
4.67 (4.06, 5.23) 4.42 (3.81, 4.97) <0.001 4.5 (3.89–5.07)
Time from HIV diagnosis to date of enrolment, months,
median (IQR)
6 (4, 9) 27 (18, 45) <0.001 17 (8, 32)
Site geographical position, n (%) 0.017
North 590 (60.1%) 916 (56.3%) 1506 (57.7%)
Center 313 (31.9%) 616 (37.9%) 929 (35.6%)
South 78 (8.0%) 95 (5.8%) 173 (6.6%)
Diabetes, n (%) 10 (1.0%) 16 (1.0%) <0.001 26 (1.0%)
Smoking, n (%) 0.950
No 327 (33.3%) 595 (36.6%) 922 (35.4%)
Yes 289 (29.5%) 592 (36.4%) 881 (33.8%)
Unknown 365 (37.2%) 440 (27.0%) 805 (30.9%)
Total cholesterol, mg/dL,
median (IQR)
165 (143, 192) 164 (140, 188) 0.395 165 (141, 189)
HDL cholesterol, mg/dL,
median (IQR)
42 (34, 48) 41 (33, 49) 0.673 41 (34, 48)
EGFR (CKD_Epi formula), ml/min/1.73m2, median (IQR) 4.67 (4.04, 5.17) 4.37 (3.63, 4.90) <0.001 4.45 (3.77, 5)
Blood glucose, mg/dL,
median (IQR)
86 (79, 92) 86 (80, 95) 0.037 86 (80, 94)
Use of statins, n (%) 5 (0.5%) 8 (0.5%) 0.353 13 (0.5%)
Use of blood pressure lowering drugs, n (%) 16 (1.6%) 35 (2.2%) 0.003 51 (2.0%)
(Continued)
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The proportion of patients achieving a HIV-RNA500 copies/mL at 6 months from the
date of starting cART was similar in RHI and NRHI and stratifying by time periods (2008–
2009: RHI 100%, NRHI 96%; 2010–2014: RHI 97%, NRHI 97%) (Table 4).
Rates and hazards of virological success from fitting a Cox regression analysis were also
similar in RHI (9.4 events/person-years of follow-up, PYFU 95%CI 8.15–10.84) versus NRHI
(9.87 events/PYFU, 95%CI 8.93–10.91; HR 0.91 of RHI versus NRHI, 95%CI 0.76–1.09).
The Kaplan Meier estimates of immune recovery showed a higher probability for RHI com-
pared to NRHI (log-rank test, p = 0.0007) (Fig 2).
In the Cox regression analysis, in fact, RHI showed a 1.5-fold higher probability of CD4+
gain200 cells/mmc (RHI: 6.85 events/PYFU, 95%CI 5.79–8.1; NRHI: 5.79 events/PYFU,
95%CI 5.09–6.6; HR 1.46 versus NRHI, 95%CI 1.18–1.81), also following adjustment for calen-
dar period and type of antiretroviral regimen started (adjusted HR 1.33, 95%CI 1.05–1.69) and
for age, HCV co-infection and smoking (adjusted HR 1.44, 95%CI 1.09–1.9); the difference in
probability was however largely attenuated after further controlling for baseline HIV-RNA
and CD4+ count (adjusted HR 1.23, 95%CI 0.98–1.54). The results were similar also exploring
the probability of immunological recovery according the second definition (CD4+ gain of 200
cells/mmc or reaching a single CD4+ count >350 cells/mmc, which ever came first): RHI, in
comparison with NRHI, presented a higher probability of CD4+ gain by fitting Kaplan Meier
curves (log-rank test p = 0.001) and Cox regression analysis (HR 1.26 versus NRHI, 95%CI
1.08–1.47), but the difference between RHI and NRHI was not confirmed after adjustment for
calendar period, type of antiretroviral regimen, age, HCV coinfection, baseline HIV-RNA and
CD4+ T cells count (adjusted HR 0.98 versus NRHI, 95%CI 0.74–1.31).
Table 1. (Continued)
Recent seroconversion
Characteristics Yes (RHI) No (NRHI) p-value Total
N 981 N 1627 N 2608
Education, n (%) <0.001
Primary school 44 (4.5%) 55 (3.4%) 99 (3.8%)
Secondary school 194 (19.8%) 354 (21.8%) 548 (21.0%)
College 307 (31.3%) 580 (35.6%) 887 (34.0%)
University 157 (16.0%) 253 (15.6%) 410 (15.7%)
Other/Unknown 279 (28.4%) 385 (23.7%) 664 (25.5%)
Employment, n (%) <0.001
Unemployed 128 (13.0%) 194 (11.9%) 322 (12.3%)
Employed 454 (46.3%) 789 (48.5%) 1243 (47.7%)
Self-employed 138 (14.1%) 284 (17.5%) 422 (16.2%)
Occasional 31 (3.2%) 48 (3.0%) 79 (3.0%)
Student 63 (6.4%) 47 (2.9%) 110 (4.2%)
Retired 15 (1.5%) 35 (2.2%) 50 (1.9%)
Invalid 1 (0.1%) 2 (0.1%) 3 (0.1%)
Housewife 20 (2.0%) 46 (2.8%) 66 (2.5%)
Other/unknown 131 (13.4%) 182 (11.2%) 313 (12.0%)
LEGEND: Categorical data are presented as absolute numbers (percentages); p values for comparison of proportions between RHI and NRHI are by Chi-
square test. Quantitative data are presented as median (Interquartile Range, IQR); p values for comparison of medians between RHI and NRHI are by
Mann Whitney test. IDUs, Intravenous Drug Users; CVD, cardiovascular diseases; EGFR, glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0189045.t001
Recent HIV infections in the Italian Cohort of Antiretroviral naïve HIV-infected patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0189045 December 5, 2017 6 / 16
Table 2. Characteristics of patients with a known date of seroconversion according to calendar period.
Period of Seroconversion
Characteristics 1996–2000 2001–2006 2007–2009 2010–2014 p-value Total
N 578 N 676 N 427 N 927 N 2608
Recent HIV infection, n (%) 213
(36.9%)
122 (18%) 120
(28.1%)
526
(56.7%)
<0.001 981 (37.6%)
Age, years–
median (IQR)
34 (30–41) 37 (31–43) 36 (29–42) 33 (27–40) <0.001 35
(30, 42)
Females, n (%) 163
(28.2%)
108 (16%) 45 (10.5%) 74 (8%) <0.001 390 (15.0%)
Mode of HIV Transmission, n (%) <0.001
IDUs 128
(22.1%)
62 (9.2%) 23 (5.5%) 30 (3.3%) 243 (9.4%)
Homosexual contacts 185
(32.0%)
376
(55.7%)
264
(62.6%)
655
(71.1%)
1480
(57.0%)
Heterosexual contacts 239
(41.3%)
207
(30.6%)
119
(27.9%)
180
(19.4%)
745 (28.6%)
Other/Unknown 26 (4.5%) 30 (4.4%) 16 (3.8%) 56 (6.1%) 128 (4.9%)
Not Italian Nationality, n (%) 40 (6.9%) 77 (11.4%) 65 (15.2%) 153
(16.5%)
0.449 335 (12.8%)
AIDS diagnosis, n (%) 33 (5.7%) 28 (4.1%) 19 (4.4%) 13 (1.4%) <0.001 93 (3.6%)
CVD diagnosis, n (%) 2 (0.3%) 2 (0.3%) 5 (1.2%) 2 (0.2%) 0.073 11 (0.4%)
HBsAg, n (%) <0.001
Negative 547
(94.6%)
659
(97.5%)
419
(98.1%)
904
(97.5%)
2529 (97%)
Positive 31 (5.4%) 17 (2.5%) 8 (1.9%) 23 (2.5%) 79 (3%)
Not tested 143
(24.7%)
244
(36.1%)
160
(37.5%)
315 (34%) 862 (33.1%)
HCV Ab, n (%) <0.001
Negative 306
(52.9%)
367
(54.3%)
258
(60.4%)
607
(65.5%)
1538 (59%)
Positive 141
(24.4%)
60 (8.9%) 25 (5.9%) 26 (2.8%) 252 (9.7%)
Not tested 131
(22.7%)
249
(36.8%)
144
(33.7%)
294
(31.7%)
818 (31.4%)
CD4 count, cells/mmc,
median (IQR)
480
(294, 670)
466
(301, 655)
448
(295, 643)
479
(331, 629)
0.566 469
(307, 651)
CD4 count nadir, cells/mmc,
median (IQR)
473
(294, 664)
460
(301, 630)
448
(293, 617)
481
(337, 643)
0.079 470
(309, 641)
CD8 count, cells/mmc,
median (IQR)
865
(657, 1196)
942
(678, 1277)
990
(728, 1428)
930
(658, 1340)
0.001 923
(675, 1283)
Viral load,
log10 copies/mL,
median (IQR)
4.35
(3.73, 5.01)
4.42
(3.78, 5.00)
4.57
(3.98, 5.00)
4.65
(4.11, 5.16)
<0.001 4.50
(3.89, 5.07)
Time from HIV diagnosis to date of enrolment, months, median
(IQR)
16 (8, 31) 33 (17, 62) 21 (11, 35) 10 (5, 18) <0.001 17 (8, 32)
Site geographical position, n (%) <0.001
North 284
(49.1%)
357
(52.8%)
256
(60.0%)
609 (66%) 1506 (57%)
Center 225
(38.9%)
278
(41.1%)
153
(35.8%)
273 (29%) 929 (37%)
South 69 (11.9%) 41 (6.1%) 18 (4.2%) 45 (4.9%) 173 (6%)
Diabetes, n (%) 5 (0.9%) 6 (0.9%) 9 (2.1%) 6 (0.6%) 0.083 26 (1.0%)
Smoking, n (%) <0.001
(Continued)
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Discussion
Trough the analysis of the data of untreated HIV-positive patients enrolled in an Italian cohort
with documented dates of HIV-negative and positive serological tests, we tried to bridge the
Table 2. (Continued)
Period of Seroconversion
Characteristics 1996–2000 2001–2006 2007–2009 2010–2014 p-value Total
N 578 N 676 N 427 N 927 N 2608
No 100
(17.3%)
262
(38.8%)
169
(39.6%)
391
(42.2%)
922 (35.4%)
Yes 157
(27.2%)
265
(39.2%)
156
(36.5%)
303
(32.7%)
881 (33.8%)
Unknown 321
(55.5%)
149
(22.0%)
102
(23.9%)
233
(25.1%)
805 (30.9%)
Total cholesterol, mg/dL, median (IQR) 164
(141, 195)
162
(137, 187)
166
(141, 190)
165
(143, 189)
0.380 165
(141, 189)
HDL cholesterol, mg/dL, median (IQR) 40 (32, 48) 41 (33, 50) 42 (34, 48) 41 (34, 48) 0.785 41 (34, 48)
EGFR
(CKD_Epi formula), ml/min/1.73m2, median (IQR)
4.20
(3.56, 5)
4.37
(3.63, 4.99)
4.52
(3.90, 4.91)
4.71
(4.04, 5.17)
0.002 4.45
(3.77, 5.00)
Blood glucose, mg/dL, median (IQR) 87 (81, 95) 86 (80, 93) 87 (80, 94) 85 (79, 93) 0.011 86 (80, 94)
Use of statins, n (%) 1 (0.2%) 5 (0.7%) 2 (0.5%) 5 (0.5%) 0.559 13 (0.5%)
Use of blood pressure lowering drugs, n (%) 3 (0.5%) 22 (3.3%) 9 (2.1%) 17 (1.8%) 0.006 51 (2.0%)
Started ART over 3 months after enrolment, n (%) 272
(47.1%)
255
(37.7%)
182
(42.6%)
458
(49.4%)
<0.001 1167
(44.7%)
Education, n (%) <0.001
Primary school 49 (8.5%) 18 (2.7%) 14 (3.3%) 18 (1.9%) 99 (3.8%)
Secondary school 201
(34.8%)
160
(23.7%)
67 (15.7%) 120
(12.9%)
548 (21.0%)
College 157
(27.2%)
247
(36.5%)
164
(38.4%)
319
(34.4%)
887 (34.0%)
University 43 (7.4%) 108
(16.0%)
68 (15.9%) 191
(20.6%)
410 (15.7%)
Other/Unknown 128
(22.1%)
143
(21.2%)
114
(26.7%)
279
(30.1%)
664 (25.5%)
Employment, n (%) <0.001
Unemployed 104
(18.0%)
80 (11.8%) 41 (9.6%) 97 (10.5%) 322 (12.3%)
Employed 260
(45.0%)
360
(53.3%)
204
(47.8%)
419
(45.2%)
1243
(47.7%)
Self-employed 107
(18.5%)
101
(14.9%)
77 (18.0%) 137
(14.8%)
422 (16.2%)
Occasional 25 (4.3%) 21 (3.1%) 11 (2.6%) 22 (2.4%) 79 (3.0%)
Student 13 (2.2%) 23 (3.4%) 13 (3.0%) 61 (6.6%) 110 (4.2%)
Retired 13 (2.2%) 21 (3.1%) 8 (1.9%) 8 (0.9%) 50 (1.9%)
Invalid 2 (0.3%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 3 (0.1%)
Housewife 43 (7.4%) 13 (1.9%) 6 (1.4%) 4 (0.4%) 66 (2.5%)
Other/unknown 11 (1.9%) 57 (8.4%) 67 (15.7%) 178
(19.2%)
313 (12.0%)
LEGEND: Categorical data are presented as absolute numbers (percentages); p values for comparison of proportions among different calendar periods are
by Chi-square test. Quantitative data are presented as median (Interquartile Range, IQR); p values for comparison of medians among different calendar
period are by Kruskal-Wallis test. IDUs, Intravenous Drug Users–ART, HIV combination antiretroviral therapy, EGFR, glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0189045.t002
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Table 3. Parameters associated with Recent HIV Infections (RHI) by univariate and multivariate logistic regression analysis.
Odds ratios of recent seroconversion
Characteristic Unadjusted OR
(95% CI)
p-value Adjusted OR
(95% CI)
p-value
Calendar period of Seroconversion
1996–2000 1 1
2001–2006 0.38 (0.29, 0.49) <0.001 1.04 (0.67, 1.61) 0.858
2007–2009 0.67 (0.51, 0.88) 0.004 1.48 (0.91, 2.41) 0.115
2010–2014 2.25 (1.82, 2.78) <0.001 12.01 (6.69, 21.57) <0.001
Gender
Female vs. male 0.67 (0.53, 0.85) <0.001 0.66 (0.37, 1.20) 0.175
Mode of HIV Transmission
IDUs 1 1
Homosexual contacts 1.36 (1.02, 1.82) 0.034 1.08 (0.50, 2.31) 0.843
Heterosexual contacts 1.09 (0.80, 1.48) 0.596 0.90 (0.42, 1.94) 0.796
Other/Unknown 1.72 (1.11, 2.67) 0.016 1.86 (0.65, 5.35) 0.250
Nationality
Not Italian vs. Italian 0.96 (0.75, 1.21) 0.717
AIDS diagnosis
Yes vs. No 0.63 (0.40, 1.00) 0.052 1.56 (0.64, 3.78) 0.328
HCV Ab
Negative 1 1
Positive 0.72 (0.54, 0.95) 0.021 0.82 (0.42, 1.61) 0.560
Not tested 0.87 (0.73, 1.03) 0.113 0.65 (0.42, 1.00) 0.050
Age, years
per 10 years older 0.77 (0.69, 0.86) <0.001 0.78 (0.65, 0.95) 0.011
CD4 count, cells/mmc
per 100 cells higher 1.05 (1.02, 1.08) 0.003 1.09 (1.03, 1.16) 0.004
CD8 count, cells/mmc
per 100 cells higher 1.00 (1.00, 1.01) 0.208
Viral load, log10 copies/mL
per log copies/mL higher 1.34 (1.22, 1.48) <0.001 1.41 (1.16, 1.71) <0.001
Diabetes
Yes vs. No 1.04 (0.47, 2.29) 0.928
Smoking
No 1 1
Yes 0.89 (0.73, 1.08) 0.233 1.25 (0.88, 1.78) 0.219
Unknown 1.51 (1.24, 1.83) <0.001 1.43 (0.84, 2.42) 0.185
Total cholesterol, mg/dL
per 10 mg/dL higher 1.15 (0.93, 1.44) 0.204
HDL cholesterol, mg/dL
per 100 mg/dL higher 0.72 (0.31, 1.68) 0.447
Use of statins
Yes vs. No 1.04 (0.34, 3.18) 0.949
Use of blood pressure lowering drugs
Yes vs. No 0.75 (0.42, 1.37) 0.354
Blood glucose, mg/dL
per 100 mg/dL higher 0.44 (0.22, 0.85) 0.015 0.69 (0.24, 1.99) 0.490
Site geographical position
(Continued )
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gap of lack of monitoring regarding the recent HIV infections. The knowledge of proportion
and epidemiological features of new HIV infections is in fact essential in order to address
screening services and try to control HIV epidemics. HIV test is the first step of the prevention
interventions; in spite of the increased numbers of persons at risk of having HIV infection that
are tested, still an unacceptable high proportion is not screened annually [16]. Since the aware-
ness of HIV infection allows linkage to care, access to cART and virological suppression, with
a reduced probability of HIV transmission, prevention measures are crucial to the reduction
of HIV-related morbidity and mortality [17–19].
Among people in the ICONA cohort for whom the date of seroconversion could be accu-
rately estimated, we hereby describe a significant trend for an increased proportion of RHI
over time (57% in 2010–2014). This could be related to the increase in prevalence of MSM in
Table 3. (Continued)
Odds ratios of recent seroconversion
Characteristic Unadjusted OR
(95% CI)
p-value Adjusted OR
(95% CI)
p-value
North 1 1
Center 0.79 (0.66, 0.94) 0.007 1.02 (0.71, 1.45) 0.930
South 1.27 (0.93, 1.75) 0.133 1.24 (0.66, 2.30) 0.505
Education
University 1
Primary/Secondary school 0.94 (0.73, 1.21) 0.622
College 0.85 (0.67, 1.09) 0.199
Other/Unknown 1.17 (0.91, 1.50) 0.227
Employment
Unemployed 1 1
Employed 0.87 (0.68, 1.12) 0.286 0.71 (0.42, 1.19) 0.197
Self-employed 0.74 (0.54, 1.00) 0.047 0.82 (0.44, 1.54) 0.543
Occasional 0.98 (0.59, 1.62) 0.934 0.90 (0.37, 2.19) 0.814
Student 2.03 (1.31, 3.15) 0.002 0.89 (0.35, 2.27) 0.815
Retired/Invalid/Housewife 0.66 (0.42, 1.03) 0.068 1.00 (0.41, 2.42) 0.995
Other/unknown 1.09 (0.79, 1.50) 0.590 0.60 (0.28, 1.30) 0.197
LEGEND: Univariate and multivariate logistic regression analysis; OR: odds ratio– 95%CI, 95% confidence interval. IDUs, Intravenous Drug Users–cART,
HIV combination antiretroviral therapy. Parameters included in the multivariable logistic regression model were calendar period of seroconversion, gender,
mode of HIV transmission, age, HCV coinfection, AIDS diagnosis, CD4+ T-cells count and HIV-RNA (measured at enrolment), employment status,
smoking, blood glucose and site geographical position.
https://doi.org/10.1371/journal.pone.0189045.t003
Table 4. Proportion of patients achieving a HIV-RNA500 copies/mL at 6 months from the date of
starting cART.
Calendar Period of enrolment
1996–2000 2001–2007 2008–2009 2010–2015
RHI 6/8 (75%) 27/30 (90%) 20/20 (100%) 176/182 (97%)
NRHI - 38/42 (90%) 41/43 (96%) 349/360 (97%)
Total 6/8 (75%) 65/72 (90%) 61/63 (97%) 525/542 (97%)
LEGEND: RHI, Recent HIV Infections; NRHI, Non Recent HIV Infections. Data are presented as absolute
numbers (percentages).
https://doi.org/10.1371/journal.pone.0189045.t004
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recent years as well as an increase in self-awareness of risky behavior in this specific patient
group [20, 21]. In our study we found no difference in mode of HIV transmission between
RHI and NRHI; conversely, from 1996–2000 to most recent periods there was a decline in the
proportion of IDUs and a significant increase in MSM (from 32% to 71%) in agreement with
Italian data of the “Istituto Superiore di Sanità” and data of European Centre for Disease Pre-
vention and Control (ECDC) about new HIV infections; the last report in fact described that
in Italy the majority of new HIV infections were sexually acquired with 44.9% in heterosexuals
and 40.6% in homosexuals [22, 23]. MSM are still vulnerable to HIV infection, as documented
by the persistence of high prevalence of infection in this group, despite an overall decline of
new infections in the general population [21, 24]. Data from the US Center of Disease Control
and Prevention (CDC) report that 54% of estimated HIV diagnoses in United States in 2014
are in MSM, even if they represent only the 2% of the population [25]. A previous Italian study
reported an increased risk of HIV seroconversion in younger MSM throughout the study
period (1984–2010) [26]; similar data were confirmed in other European studies with a double
risk of HIV in MSM aging 20–29 years from 2003 to 2012 [27, 28].
Our results are in keeping with the results from other European studies: the prevalence of
recent infections varied from 7 to 47% due to differences in the prevalence of HIV infection in
European countries, the analyzed study period and the definition of recent infection. All the
other European studies described a shift in HIV risk from IDUs to sexual transmission in most
recent years [29–31].
Policies of HIV prevention have changed over recent years acquiring new effective tools
and targeting groups at risk in areas most affected by HIV epidemics. Our finding of an
Fig 2. Probability of immune recovery (time from cART start to CD4+ count gain200 cells/mmc) by Kaplan Meier estimates. Kaplan Meier
estimates of the probability of achieving CD4+ T-cells count200 cells/mmc from cART start according to Recent and non Recent HIV Infection; log rank test.
The continuous line represents Less Recent HIV Infections (NRHI), the dot line represents Recent HIV Infections (RHI).
https://doi.org/10.1371/journal.pone.0189045.g002
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increased proportion of RHI might also reflect an increase of rate of HIV testing as a result of
the introduction and implementation of ‘test and treat’ policies [32]. Currently, however, pre-
vention services need to be monitored to identify weak areas to be improved. In fact, according
to the last ECDC reports about HIV infection in the European Union, prevention interven-
tions are still not enough to reduce the number of new HIV infections; in comparison with the
UNAIDS 90:90:90 target, 15–17% of people living with HIV in Europe are estimated to have
not yet been diagnosed, and among people diagnosed with HIV, nearly half are diagnosed late.
Furthermore, 17% of people diagnosed with HIV are still not on treatment and the proportion
of patients receving cART that are virally suppressed is around 51–95% [23].
By 3 months from seroconversion cART was started in half of the patients without signifi-
cant differences between RHI and NRHI, but this analysis was performed before the results of
the START trial became public [6].
The benefits of early treatment are now well recognized [33]: the 5-year risk of clinical pro-
gression is 3.2% in people starting cART immediately versus 7% in those deferring [34]. Rapid
cART initiation is known to confer a significantly enhanced 2 year probability of immunologi-
cal recovery, independently from baseline CD4+ count, and minimized HIV-associated
inflammation [9]. These benefits translate in a reduced clinical progression in previous cohort
studies [10, 11]. Similarly, retrospective studies have shown that long pretreatment waiting
time in HIV-positive patients is associated with a higher risk of reduced cART adherence and
subsequent higher mortality [35]. As previously demonstrated by HPTN052 trial, besides
reducing AIDS and non AIDS related diseases, early cART initiation is also associated with a
reduction of 96% in HIV transmission [18, 36]. Similarly, during a median follow-up of 1.3
years no cases of HIV transmission have been reported among serodifferent couples when the
HIV-positive partner was under virally suppressive cART [18]. Our study reports data from
1996 to 2014; in the previous periods Italian guidelines suggested starting cART with a CD4
+ count below 200 cells/mmc and then 350 cells/mmc. Most recent guidelines recommend
that cART is offered to all HIV-positive patients, irrespective of CD4+ counts, also in order to
reduce risk of transmission. Thus, in agreement with the UNAIDS 90:90:90 target [37], a
reduction in HIV transmission is foreseeable that reflects the increasing number of HIV-posi-
tive patients on successful treatment.
Despite these data on clinical and immunologic advantages of treatment in the recent or
acute phase [10, 11, 38], in our cohort we found similar rates of immune-virological response
in RHI and NRHI; reasons are unclear, but it is possible that in the era of modern cART with
highly effective and tolerated regimens differences are attenuated. Researchers of the Swiss
HIV cohort showed that a substantial fraction of HIV transmissions can be attributed to
recently infected patients, for whom the preventive effect of treatment is weaker, due to under-
diagnosis and lack of patient’s awareness of their seropositive status [3]. Thus, early testing and
the use of antiretroviral drugs associated with a rapid viral decay in RHI is crucial to maximize
the effect of cART use as prevention and to reduce the risk of HIV transmission.
The main limitation of our analysis is the lack of differentiation between acute HIV and
RHI (symptoms of acute infection are not collected in the cohort) and the potential selection
bias introduced by including only cohort participants for whom the date of seroconversion
could be accurately estimated; however, the increase of prevalence of MSM at enrolment has
been also shown in analyses including the whole cohort. Furthermore, not all HIV-infected
patients in Italy are enrolled in the ICONA cohort due to the design based upon voluntary
enrolment. Finally, our finding of regional differences in the different calendar periods might
reflect several changes in the centers participating to ICONA occurred in most recent years.
Despite such limitations our data are in line with epidemiological reports by the “Istituto
Superiore di Sanità” [22].
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Conclusions
The increased proportion of RHI over time in our cohort suggests that in recent years in Italy
people are diagnosed earlier with HIV and more quickly enter care after the diagnosis.
National data in fact show that the incidence of new HIV infections remained stable over the
study period; nevertheless, efforts to the development and implementation of effective preven-
tion interventions should continue to guarantee broad early cART access, reduce new infec-
tions and get closer to the UNAIDS 90-90-90 target.
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